Evans syndrome
MONDO:0016030Evans syndrome is a rare chronic hematologic disorder characterized by the simultaneous or sequential association of autoimmune hemolytic anemia (AIHA; a disorder in which auto-antibodies are directed against red blood cells causing anemia of varying degrees of severity) with immune thrombocytopenic purpura (ITP; a coagulation disorder in which auto-antibodies are directed against platelets causing hemorrhagic episodes) and occasionally autoimmune neutropenia, in the absence of a known underlying etiology.
Also known as: Evans' syndrome, autoimmune hemolytic anaemia and autoimmune thrombocytopenia, autoimmune hemolytic anemia and autoimmune thrombocytopenia, immune pancytopenia, Evan syndrome
64 clinical trials for this condition and its sub-types, 19 tagged with Evans syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Engineered immune cells take aim at stubborn blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing anemia. META 10-19 uses a patien…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Selective cell removal may tame stem cell Transplant's dangerous side effect
Disease control Not yet recruitingThis study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental CAR-T therapy takes on stubborn blood disorder
Disease control Not yet recruitingThis early-phase study tests a new treatment called IASO206 for people whose autoimmune hemolytic anemia (AIHA) has not responded to standard therapies. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing fatigue and other symptoms. The study …
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cell therapy offers hope for tough anemia cases
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The …
Phase 1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cell therapy takes on tough blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called YTS109 in 13 adults with autoimmune hemolytic anemia that has not responded to at least three prior treatments. The therapy uses specially engineered immune cells to target and control the disease. The main goals are to check…
Phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose.…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare blood disorder: linprixel trial launches
Disease control Not yet recruitingThis phase 2 trial tests linprixel, a daily pill, in 22 adults with relapsed or refractory autoimmune hemolytic anemia (AIHA). The study aims to see if the drug can improve red blood cell counts after 12 weeks. Participants start at 40mg daily, with possible dose increases if nee…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC